EGFR and chronic obstructive pulmonary disease: We hypothesize that the COPD-associated chronic inflammatory microenvironment (e.g., elevated IL-6 or TNF-α levels) may impair the efficacy of EGFR-TKI therapy through activation of the JAK/STAT signaling pathway, a hypothesis requiring experimental validation.